Evaluation of pharmacological therapies for Friedreich ataxia using cellular and mouse models

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/491234

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Friedreich ataxia (FRDA) is an inherited disorder of the nervous system and muscles. The genetic defect that causes FRDA results in reduced levels of an essential protein termed frataxin. By using information and resources generated as part of the Human Genome Project we have developed new techniques to study human gene expression in cellular and animal systems. Our aim is to identify and develop new pharmacological approaches for the restoration of FRDA gene expression and the therapy of FRDA.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $589,425.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical microbiology not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Friedreich ataxia | Genetic disease | Neurological disease | Pharmacological intervention | Therapy with biopharmaceuticals | Transgenic animals

Related Links